Foghorn Therapeutics to Participate in the BMO Oncology Summit

Rhea-AI Summary

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company, has announced its participation in investor meetings at the BMO Oncology Summit on October 8, 2024, in New York, NY. The company is pioneering a new class of medicines that aim to correct abnormal gene expression to treat serious diseases.

Foghorn's Gene Traffic Control® platform and resulting broad pipeline focus initially on oncology but have the potential to address a wide spectrum of diseases. This innovative approach could potentially transform the lives of many patients suffering from various conditions.

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in investor meetings at the BMO Oncology Summit being held Tuesday, October 8, 2024, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control^® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

About Foghorn Therapeutics
Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information about the Company, and follow us on X and LinkedIn.

Contact:

Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
khellsvik@foghorntx.com

FAQ

When and where is Foghorn Therapeutics (FHTX) participating in the BMO Oncology Summit?

Foghorn Therapeutics (FHTX) is participating in the BMO Oncology Summit on Tuesday, October 8, 2024, in New York, NY.

What is the focus of Foghorn Therapeutics' (FHTX) Gene Traffic Control® platform?

Foghorn Therapeutics' (FHTX) Gene Traffic Control® platform initially focuses on oncology but has the potential to address a wide spectrum of diseases by correcting abnormal gene expression.

What type of company is Foghorn Therapeutics (FHTX)?

Foghorn Therapeutics (FHTX) is a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression.

How might Foghorn Therapeutics' (FHTX) pipeline impact patients?

Foghorn Therapeutics' (FHTX) broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases, starting with oncology.